The acquisition of biotechnology firms is one of the most common ways big pharma replenishes their pipeline of new drugs. However,…
McAlinden Research PartnersMay 12, 2022
The COVID-19 omicron variant has diminished the efficacy of the US's most prominent antibody treatments. As the genome of this virus constantly…
McAlinden Research PartnersJanuary 4, 2022
Most data indicates M&A activity has slowed in the pharmaceutical and biotech industries. However, that may change in 2022 as…
McAlinden Research PartnersDecember 22, 2021
US drug store chains are set to experience heightened foot traffic now that all adults are eligible for booster shots…
McAlinden Research PartnersNovember 29, 2021
Psychedelic drugs and therapies continue to show promise as a form of treatment for a wide variety of mental health disorders.…
McAlinden Research PartnersOctober 18, 2021
Drug stores could be set to boost their revenues as COVID-19 restrictions ease and vaccine booster shot plans continue to…
McAlinden Research PartnersOctober 4, 2021
Research into CRISPR gene editing technology continues to expand the amount of potential applications, while shrinking the actual size of proteins…
McAlinden Research PartnersSeptember 8, 2021
AI is transforming industries across every sector of the economy. Biotech and pharma are now experiencing a boom in AI initiatives…
McAlinden Research PartnersJuly 27, 2021
Promising developments in new gene editing trials continue to drive investor interest in the growing biotech sector. Potential advancements include the…
McAlinden Research PartnersJuly 22, 2021
